Latest Healthcare News

Anteris Technologies has treated the first US patients in its global PARADIGM trial, marking a key milestone in testing its DurAVR transcatheter heart valve against established devices.

Careteq Limited has cleared $125,000 in director and company secretary loans a month ahead of schedule, using proceeds from a recent $2.2 million capital raising. This move strengthens the healthtech firm’s balance sheet and removes related-party debt ahead of maturity.

Resonance Health upgrades its FY26 underlying EBITDA guidance to $2.6 million, driven by operational efficiencies and growth in its Software-as-Medical Devices segment, despite a slight revenue timing delay.

Nova Eye Medical has smashed its US sales record in April 2026, prompting an upgrade to its FY26 sales guidance and marking a milestone with positive operational EBITDA.

Cann Group’s CEO Jenni Pilcher steps down after leading a dramatic debt reduction and cost overhaul. Chairman Mike Ryan takes interim charge as the company hunts for a new CEO.

Emyria Limited reported $1.2 million in revenue for the March quarter, driven by insurer-funded clinics and strong clinical outcomes in PTSD treatment. The company is advancing its national clinic rollout, including new sites in Victoria and New South Wales, while launching a global partnership program targeting international drug sponsors.

Sigma Healthcare reports robust growth in Chemist Warehouse sales across Australia and internationally, announces a joint venture to enter the UK market, and secures a major distribution centre lease in New Zealand to support its expanding network.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.

PYC Therapeutics presented Phase 1/2 data at ARVO 2026 showing encouraging safety and efficacy signals for its RNA therapies targeting rare genetic eye diseases Retinitis Pigmentosa type 11 and Autosomal Dominant Optic Atrophy.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.

Entropy Neurodynamics has unveiled a striking 75% response rate in a small Phase 2a trial of its oral psilocybin therapy for treatment-resistant irritable bowel syndrome, far surpassing existing treatments and validating its gut-brain axis approach.